Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis

BACKGROUND: A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Godolphin, Peter J., Fisher, David J., Berry, Lindsay R., Derde, Lennie P. G., Diaz, Janet V., Gordon, Anthony C., Lorenzi, Elizabeth, Marshall, John C., Murthy, Srinivas, Shankar-Hari, Manu, Sterne, Jonathan A. C., Tierney, Jayne F., Vale, Claire L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269978/
https://www.ncbi.nlm.nih.gov/pubmed/35802687
http://dx.doi.org/10.1371/journal.pone.0270668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269978/
https://www.ncbi.nlm.nih.gov/pubmed/35802687
http://dx.doi.org/10.1371/journal.pone.0270668

Ejemplares similares